<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642600</url>
  </required_header>
  <id_info>
    <org_study_id>S61338</org_study_id>
    <nct_id>NCT03642600</nct_id>
  </id_info>
  <brief_title>The Gut Microbiome in Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing two different strategies for weight loss intervention and revealing possible changes&#xD;
      in composition of gut microbiota, in order to provide more insight in the effect of dietary&#xD;
      changes and weight loss treatments on gut microbiome in overweight and obese women with&#xD;
      polycystic ovary syndrome (PCOS). The two strategies are:&#xD;
&#xD;
        -  dietary advice plus myo-inositol and folic acid&#xD;
&#xD;
        -  dietary advice plus liraglutide, glucagon-like peptide-1 (GLP-1) receptor agonist&#xD;
           Primary outcome will be weight loss. Secondary outcomes are longitudinal changes in&#xD;
           clinical features associated with PCOS and metabolic syndrome, longitudinal changes in&#xD;
           gut microbiome with interventions.&#xD;
&#xD;
      Subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Actual">July 3, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>PCOS</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>dietary advice plus myo-inositol and folic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary advice plus liraglutide pen injector</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>dietary advice plus myo-inositol and folic acid</intervention_name>
    <description>dietary advice and lifestyle interventions and myo-inositol</description>
    <arm_group_label>dietary advice plus myo-inositol and folic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dietary advice plus Liraglutide Pen Injector</intervention_name>
    <description>dietary advice and lifestyle interventions and liraglutide pen injector</description>
    <arm_group_label>dietary advice plus liraglutide pen injector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS according to ROtterdam criteria&#xD;
&#xD;
          -  BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  pancreatitis (in the past)&#xD;
&#xD;
          -  oral contraceptive pill use&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  auto-immune disease&#xD;
&#xD;
          -  immuno-modulatory drugs&#xD;
&#xD;
          -  antidiabetic drugs&#xD;
&#xD;
          -  anti-inflammatory drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Lie Fong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharon Lie Fong</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

